SG11202008435SA - Pharmaceutical composition including sodium alkyl sulfate - Google Patents

Pharmaceutical composition including sodium alkyl sulfate

Info

Publication number
SG11202008435SA
SG11202008435SA SG11202008435SA SG11202008435SA SG11202008435SA SG 11202008435S A SG11202008435S A SG 11202008435SA SG 11202008435S A SG11202008435S A SG 11202008435SA SG 11202008435S A SG11202008435S A SG 11202008435SA SG 11202008435S A SG11202008435S A SG 11202008435SA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
composition including
alkyl sulfate
sodium alkyl
including sodium
Prior art date
Application number
SG11202008435SA
Inventor
Kenji Kusumoto
Sadahiro MIYAMURA
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11202008435SA publication Critical patent/SG11202008435SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
SG11202008435SA 2018-03-19 2019-03-18 Pharmaceutical composition including sodium alkyl sulfate SG11202008435SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018051620 2018-03-19
PCT/JP2019/011251 WO2019181876A1 (en) 2018-03-19 2019-03-18 Pharmaceutical composition including sodium alkyl sulfate

Publications (1)

Publication Number Publication Date
SG11202008435SA true SG11202008435SA (en) 2020-10-29

Family

ID=67987327

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008435SA SG11202008435SA (en) 2018-03-19 2019-03-18 Pharmaceutical composition including sodium alkyl sulfate

Country Status (15)

Country Link
US (1) US11833151B2 (en)
EP (2) EP4353222A1 (en)
JP (2) JP6918204B2 (en)
KR (1) KR102473372B1 (en)
CN (1) CN111867594A (en)
AU (1) AU2019239404B2 (en)
BR (1) BR112020018697A2 (en)
CA (1) CA3094431C (en)
MA (1) MA52093A (en)
MX (1) MX2020009762A (en)
PH (1) PH12020551412A1 (en)
RU (1) RU2759746C1 (en)
SG (1) SG11202008435SA (en)
TW (1) TWI790364B (en)
WO (1) WO2019181876A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR102473372B1 (en) * 2018-03-19 2022-12-05 다이호야쿠힌고교 가부시키가이샤 Pharmaceutical composition containing sodium alkyl sulfate
KR20210095659A (en) * 2018-11-26 2021-08-02 다이호야쿠힌고교 가부시키가이샤 A method for treating and preventing tumors to which endocrine therapy is applied by using a combination of a fibroblast growth factor receptor inhibitor and endocrine therapy
WO2023238929A1 (en) * 2022-06-10 2023-12-14 大鵬薬品工業株式会社 Pharmaceutical composition containing pimitespib

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3433239A1 (en) 1984-09-11 1986-03-20 Bayer Ag, 5090 Leverkusen SOLID PHARMACEUTICAL PREPARATION CONTAINING NITRENDIPINE AND METHOD FOR THE PRODUCTION THEREOF
FR2758459B1 (en) 1997-01-17 1999-05-07 Pharma Pass FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
JP4117811B2 (en) 1997-04-22 2008-07-16 日本化薬株式会社 Flutamide preparation and its production method
AU6853498A (en) * 1997-04-22 1998-11-13 Nippon Kayaku Kabushiki Kaisha Flutamide preparations and method for manufacturing the same
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
EE05450B1 (en) 2000-07-19 2011-08-15 Warner-Lambert Company Oxygenated esters of 4-iodophen laminobenzh droxamic acids, their crystalline forms and pharmaceutical compositions and their use
PT3000810T (en) 2002-03-13 2017-10-25 Array Biopharma Inc N3 alkylated benzimidazole derivative as mek inhibitor
ATE481985T1 (en) 2002-07-03 2010-10-15 Ono Pharmaceutical Co IMMUNOPOTENTATING COMPOSITIONS
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US7772234B2 (en) 2003-11-19 2010-08-10 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
DE10355461A1 (en) 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
PL1761528T3 (en) 2004-06-11 2008-05-30 Japan Tobacco Inc 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
DK1802579T3 (en) 2004-10-20 2014-01-20 Merck Serono Sa Derivatives of 3-arylaminopyridine
CN101233139A (en) * 2005-06-17 2008-07-30 辉瑞有限公司 Alpha-(aryl-or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as ORL1-receptor antagonists
MX2008002114A (en) 2005-07-21 2008-04-17 Ardea Biosciences Inc N-(arylamino)-sulfonamide inhibitors of mek.
RU2008117298A (en) 2005-10-06 2009-11-20 Шеринг Корпорейшн (US) Pyrazolopyrimidines as Protein Kinase Inhibitors
JP5129143B2 (en) 2005-10-07 2013-01-23 エグゼリクシス， インコーポレイテッド MEK inhibitor and method of use thereof
CN102887891B (en) 2005-11-15 2016-03-09 阿雷生物药品公司 N4-phenyl-quinazoline-4-sulfonamide derivatives and related compound
TW200738725A (en) 2006-01-25 2007-10-16 Osi Pharm Inc Unsaturated mTOR inhibitors
CA2597740C (en) 2006-04-26 2012-10-16 Supernus Pharmaceuticals, Inc. Modified-release preparations containing oxcarbazepine and derivatives thereof
EP1939197A1 (en) 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
JP5319306B2 (en) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composition for treatment of undifferentiated gastric cancer
CN101674834B (en) 2007-03-28 2013-06-12 环状药物公司 Inhibitors of bruton's tyrosine kinase
PL2139484T3 (en) 2007-04-10 2013-12-31 Exelixis Inc Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
RU2453332C2 (en) * 2007-10-16 2012-06-20 Байокон Лимитид Solid pharmaceutical composition (versions) and method for controlling glucose concentration therewith, method for preparing solid pharmaceutical compositions (versions), tablet (versions) and method for making amorphous particles
CN102123989A (en) 2008-06-19 2011-07-13 阿斯利康(瑞典)有限公司 Pyrazole compounds 436
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
MX2011011516A (en) 2009-04-30 2011-11-18 Astex Therapeutics Ltd Imidazole derivatives and their use as modulators of cyclin dependent kinases.
KR101483215B1 (en) 2010-01-29 2015-01-16 한미약품 주식회사 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinases
WO2011115937A1 (en) 2010-03-14 2011-09-22 The Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
CN106963741A (en) * 2010-03-29 2017-07-21 Ea制药株式会社 Pharmaceutical preparation containing Phenylalamine derivatives
DE102011015188A1 (en) 2010-03-29 2011-09-29 Herbert Kannegiesser Gmbh Process for wet treatment, in particular for cleaning, articles
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
AR083417A1 (en) 2010-10-14 2013-02-21 Novartis Ag PHARMACEUTICAL COMPOSITIONS CONTAINING AN INHIBITOR DGAT1
MX342064B (en) 2011-04-06 2016-09-12 Taiho Pharmaceutical Co Ltd Novel imidazo-oxazine compound or salt thereof.
UY34484A (en) 2011-12-15 2013-07-31 Bayer Ip Gmbh BENZOTIENILO-PIRROLOTRIAZINAS DISUSTITUIDAS AND ITS USES
SG2014009286A (en) 2012-01-19 2014-04-28 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
BR112014017985A8 (en) 2012-01-31 2017-07-11 Novartis Ag COMBINATION OF AN RTK INHIBITORS WITH AN ANTISTROGEN AND THEIR USE FOR THE TREATMENT OF CANCER
WO2013124316A1 (en) 2012-02-23 2013-08-29 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
EP2868660B1 (en) 2012-07-02 2017-12-27 Taiho Pharmaceutical Co., Ltd. Antitumor effect potentiator comprising an imidazooxazine compound
CN103570725B (en) 2012-08-01 2017-03-22 中国科学院上海药物研究所 Piperazidinoltriazole compound as well as preparation method and application thereof
JP6463687B2 (en) 2012-11-26 2019-02-06 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ Compositions and methods for modulation of FGFR3 expression
KR20150123250A (en) 2013-03-06 2015-11-03 제넨테크, 인크. Methods of treating and preventing cancer drug resistance
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
EP3012327B1 (en) 2013-06-20 2020-12-16 Taiho Pharmaceutical Co., Ltd. METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF PI3K/AKT/mTOR INHIBITOR ON BASIS OF PHLDA1 OR PIK3C2B EXPRESSION
WO2015008844A1 (en) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Therapeutic agent for fgfr inhibitor-resistant cancer
JP6084291B2 (en) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Antitumor agent for intermittent administration of FGFR inhibitor
BR112016022620A2 (en) 2014-03-31 2017-10-10 Debiopharm Int Sa cdna encoding a fusion polypeptide, vector, prokaryotic or eukaryotic cell, polynucleotide sequence, fusion polypeptide, antibody or binding fragment, primer pair, oligonucleotide probe, oligonucleotide, sirna, fgfr kinase activity inhibitor, therapy method and method to identify a compound
TWI720943B (en) 2014-04-25 2021-03-11 日商中外製藥股份有限公司 Formulation comprising tetracyclic compounds in high dose
CN105017256A (en) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 Polyfluorinated compound Bruton tyrosine kinase inhibitor
WO2015173853A1 (en) * 2014-05-12 2015-11-19 株式会社日立製作所 Information-processing device, processing method thereof, and input/output device
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
MA41350A (en) 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv SUMMARY OF A BRUTON TYROSINE KINASE INHIBITOR
CN105859721B (en) 2015-01-22 2018-04-17 浙江京新药业股份有限公司 A kind of Yi Bulu replaces the preparation method of Buddhist nun
CN112494653A (en) 2015-02-05 2021-03-16 特尔诺沃有限公司 Combination of IRS/STAT3 dual modulators and anticancer agents for the treatment of cancer
US10792284B2 (en) 2015-02-12 2020-10-06 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
ES2772682T3 (en) 2015-02-27 2020-07-08 Taiho Pharmaceutical Co Ltd Imidazooxazine crystal, pharmaceutical composition containing said crystal, and method of producing said crystal
HUE051074T2 (en) 2015-03-31 2021-03-01 Taiho Pharmaceutical Co Ltd Crystal of 3,5-disubstituted benzene alkynyl compound
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN108289892B (en) 2015-06-29 2021-11-23 维瑞斯特姆股份有限公司 Therapeutic compositions, combinations and methods of use
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
WO2017017516A1 (en) * 2015-07-24 2017-02-02 Debiopharm International Sa Fgfr expression and susceptibility to an fgfr inhibitor
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6860919B2 (en) 2015-11-19 2021-04-21 国立大学法人金沢大学 Mesenchymal KRAS mutant cancer therapeutic agent
WO2017150725A1 (en) * 2016-03-04 2017-09-08 大鵬薬品工業株式会社 Preparation and composition for treatment of malignant tumors
JP2018002662A (en) 2016-07-01 2018-01-11 大鵬薬品工業株式会社 Intermediate useful for synthesizing quinolylpyrrolopyrimidyl fused-ring compound
JP6296308B1 (en) 2016-09-26 2018-03-20 ツジカワ株式会社 Roll device
RU2769132C2 (en) 2017-01-10 2022-03-28 Новартис Аг Pharmaceutical combination containing alk inhibitor and shp2 inhibitor
KR102473372B1 (en) * 2018-03-19 2022-12-05 다이호야쿠힌고교 가부시키가이샤 Pharmaceutical composition containing sodium alkyl sulfate
AU2018448845B2 (en) 2018-11-09 2022-03-24 Taiho Pharmaceutical Co., Ltd. Method for producing dimethoxybenzene compound
WO2020096050A1 (en) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 Dimethoxybenzene compound analogs, methods for analyzing said compounds and standard products of said compounds
KR20210095659A (en) 2018-11-26 2021-08-02 다이호야쿠힌고교 가부시키가이샤 A method for treating and preventing tumors to which endocrine therapy is applied by using a combination of a fibroblast growth factor receptor inhibitor and endocrine therapy
WO2020170355A1 (en) 2019-02-20 2020-08-27 大鵬薬品工業株式会社 Method for treating fgfr1 mutated tumor
EP3932425A4 (en) 2019-02-28 2022-12-07 Taiho Pharmaceutical Co., Ltd. Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor
AU2020297166A1 (en) 2019-06-21 2022-02-17 Taiho Pharmaceutical Co., Ltd. Method for treating malignant tumor

Also Published As

Publication number Publication date
JPWO2019181876A1 (en) 2020-10-08
EP3769765A4 (en) 2021-12-15
MA52093A (en) 2021-01-27
KR102473372B1 (en) 2022-12-05
CN111867594A (en) 2020-10-30
JP2021167346A (en) 2021-10-21
PH12020551412A1 (en) 2021-09-01
TW201938564A (en) 2019-10-01
US20210030755A1 (en) 2021-02-04
CA3094431A1 (en) 2019-09-26
AU2019239404B2 (en) 2021-12-23
RU2759746C1 (en) 2021-11-17
KR20200131873A (en) 2020-11-24
AU2019239404A1 (en) 2020-11-05
TWI790364B (en) 2023-01-21
MX2020009762A (en) 2021-01-08
CA3094431C (en) 2023-06-27
EP4353222A1 (en) 2024-04-17
EP3769765A1 (en) 2021-01-27
US11833151B2 (en) 2023-12-05
BR112020018697A2 (en) 2020-12-29
JP7322103B2 (en) 2023-08-07
WO2019181876A1 (en) 2019-09-26
JP6918204B2 (en) 2021-08-11
EP3769765B1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
SG11202008435SA (en) Pharmaceutical composition including sodium alkyl sulfate
IL280135A (en) Elagolix sodium compositions and processes
GB201804548D0 (en) Pharmaceutical compositions
GB201818164D0 (en) New composition
GB201804434D0 (en) Composition
SI3749673T1 (en) Crystalline form of bictegravir sodium
PT3834893T (en) Fireproof composition
GB201807053D0 (en) Pharmaceutical composition
SG11202103374TA (en) Pharmaceutical composition
GB201911517D0 (en) Pharmaceutical composition
PT3632436T (en) Pharmaceutical composition comprising lenvatinib salts
GB201808571D0 (en) Pharmaceutical compositions
SG11202110315SA (en) Pharmaceutical composition
FI3908321T3 (en) Pharmaceutical composition
EP4081251A4 (en) Pharmaceutical compositions
GB201919180D0 (en) New composition of matter
GB201808567D0 (en) Pharmaceutical compositions
GB201801596D0 (en) Composition
PL3414211T3 (en) Plaster composition
ZA202006541B (en) Pharmaceutical composition comprising brexpiprazole
GB201820689D0 (en) Pharmaceutical composition
IL292715A (en) Soap composition
GB201810265D0 (en) New pharmaceutical compositions
GB201810261D0 (en) New pharmaceutical compositions
PT3749673T (en) Crystalline form of bictegravir sodium